Drug
Darexaban clinical trials
Also written YM150.
- studies test it
- 25
- open now
- 0
- in phase 3
- 7
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2009 (11)
| Year | Studies |
|---|---|
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 11 |
| 2010 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 9
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 0
Often tested with
Tested in the same studies.
Ketoconazole (1) · Naproxen (1) · Rifampin (1) · Clopidogrel (1) · Digoxin (1) · Aspirin (1)
Studies
Open first, then newest update. How each study uses darexaban is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement SurgeryCompletedPhase 2/3Astellas Pharma Europe B.V.NCT00902928Written as YM150
- Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary SyndromesCompletedPhase 2Astellas Pharma Europe B.V.NCT00994292Written as YM150
- To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)CompletedPhase 1Astellas Pharma IncNCT01405989Written as darexaban
- A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male SubjectsCompletedPhase 1Astellas Pharma Europe B.V.NCT01657981Written as YM150
- A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the BodyCompletedPhase 1Astellas Pharma Europe B.V.NCT01655056Written as YM150
- To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their EffectsCompletedPhase 1Astellas Pharma IncNCT01409603Written as darexaban
- To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)CompletedPhase 1Astellas Pharma IncNCT01406002Written as darexaban
- A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement SurgeryCompletedPhase 2Astellas Pharma IncNCT00595426Written as YM150
- To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their EffectsCompletedPhase 1Astellas Pharma IncNCT01409616Written as darexaban
- Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)CompletedPhase 2Astellas Pharma IncNCT00353678Written as YM150
- A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly SubjectsCompletedPhase 1Astellas Pharma IncNCT01514825Written as YM150
- A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy SubjectsCompletedPhase 1Astellas Pharma IncNCT01514812Written as YM150
- Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee ReplacementCompletedPhase 2Astellas Pharma IncNCT00408239Written as YM150
- Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial FibrillationCompletedPhase 2Astellas Pharma IncNCT00448214Written as YM150
- To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their EffectsCompletedPhase 1Astellas Pharma IncNCT01424332Written as Darexaban
- A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial FibrillationCompletedPhase 2Astellas Pharma IncNCT00938730Written as YM150
- Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous ThromboembolismCompletedPhase 3Astellas Pharma IncNCT00937820Written as YM150
- A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal SurgeryCompletedPhase 3Astellas Pharma IncNCT00942435Written as YM150
- YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical IllnessCompletedPhase 3Astellas Pharma IncNCT01028950Written as YM150
- Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower ExtremitiesCompletedPhase 3Astellas Pharma IncNCT00937911Written as YM150
Codes
What other systems call darexaban · ClinicalTrials.gg INT005986
- MeSH (NLM) C569750darexabanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) KF322K101SDAREXABANConfirmed FDA, NLM, Wikidata
- Wikidata Q5222570darexabanConfirmed FDA, NLM, Wikidata
- DrugBank DB12289One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C569750 | darexaban | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | KF322K101S | DAREXABAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5222570 | darexaban | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB12289 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.